Surufatinib: First Approval
Declarations
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable
Additional information about this Adis Drug Review can be found here
Abstract
Surufatinib (Sulanda®), an oral angio-immuno kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF1R, is being developed by HUTCHMED for the treatment of solid tumours, including neuroendocrine tumours (NETs). On 30
December 2020, surufatinib received its frst approval in China for the treatment of late-stage, well-diferentiated, extrapancreatic NET. Surufatinib is in preregistration in China for pancreatic NET and in the USA for pancreatic and extrapancreatic
NET; phase II development is underway for other solid tumours, including thyroid cancer, biliary tract carcinoma and soft
tissue sarcoma. This article summarizes the milestones in the development of surufatinib leading to this frst approval for
extrapancreatic NET.
© Springer Nature Switzerland AG 2021
